Market Overview:
The global atenolol API market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of hypertension and other cardiovascular diseases, rising demand for generic drugs, and growing investments by pharmaceutical companies in R&D activities. Based on type, the global atenolol API market is segmented into purity ≥ 98 % and purity ≥ 99 % segments. The purity ≥ 98 % segment is expected to account for a larger share of the market than the purity ≥ 99 % segment during the forecast period. This can be attributed to factors such as lower manufacturing costs and shorter lead times associated with products that have a higher degree of impurity. Based on application, the global atenolol API market is divided into tablets, injections, and others segments.
Product Definition:
Atenolol API is a beta blocker that is used to treat hypertension, angina and other heart conditions. It works by blocking the effects of adrenaline and other hormones that can increase the heart rate. This helps to slow down the heart rate and improve blood flow.
Purity ≥ 98 %:
Atenolol is a beta-blocker drug used for the treatment of hypertension. It works by blocking the action of angiotensin II, which causes vasoconstriction and constricts blood vessels. The product has been approved in Japan, Australia, New Zealand and South Africa for the treatment of high blood pressure.
Purity ≥ 99 %:
Purity of the product is defined as the percentage of active ingredients in a given pharmaceutical formulation. The most common way to measure purity is by HPLC analysis which includes High-Performance Liquid Chromatography (HPLC) and Gas Chromatography (GC). Purity standards are set for each batch which should contain at least 95% of an active ingredient.
In case if any impurities are found, then it can be easily removed or destroyed during purification process.
Application Insights:
The atenolol tablets application segment accounted for the largest revenue share of over 40.0% in 2017. The product is used as a beta blocker and diuretic, which helps in treating hypertension and cardiac arrhythmia respectively. Furthermore, it also has some other applications such as treatment of angina pectoris, bronchospasm, urinary retention and impotence among others.
Injection is expected to be the fastest-growing application segment owing to its ability to deliver fast acting relief in life-threatening conditions such as heart attack or stroke due to reduced blood pressure levels caused by an inadequate supply of oxygenated blood reaching the heart muscles through arteries or veins respectively.
Regional Analysis:
North America dominated the global atenolol API market in 2017. High prevalence of target diseases such as hypertension, cardiac failure, and stroke is one of the major factors responsible for its largest share. In addition, increasing number of product launches by key players in this region is also expected to drive growth over the forecast period. For instance, Sun Pharmaceutical Industries Ltd., India launched AtenolOL Tablets 50 mg and 100 mg dosage forms in January 2016 for treating hypertension.
Asia Pacific is expected to be the fastest-growing regional market during the forecast period owing to high unmet medical needs coupled with rising disposable income levels among patients & their families especially in emerging countries such as China & India which are amongst top 20 pharmaceutical markets globally along with Japan and South Korea respectively contributing significantly towards overall APAC revenue generation capacity expansion etc.
Growth Factors:
- Increasing prevalence of hypertension and other heart diseases: The global prevalence of hypertension is expected to increase from 972 million in 2015 to 1.5 billion by 2025, according to a study by the World Health Organization (WHO). This will create a large pool of patients who will require treatment with Atenolol API or its formulations.
- Growing demand for generic drugs: The global generics market is projected to grow at a CAGR of 8% from 2016-2021, owing to the increasing preference for low-cost generic drugs over branded therapies. This will provide lucrative growth opportunities for players in the Atenolol API market.
- Rising awareness about heart health: There has been an increasing awareness among people about the importance of maintaining good heart health and preventing heart diseases through lifestyle changes and preventive measures such as medication therapy. This is likely to boost demand for Atenolol API in the coming years.
- Technological advancements in drug delivery systems: Drug delivery technologies are evolving rapidly, with new systems being developed that offer improved patient compliance and convenience compared with traditional oral dosage forms like tablets and capsules .This is likely to fuel demand for Atenolol API in various drug delivery formats such as patches, implants, nasal sprays etc., over the next few years.. 5) Expanding product pipeline: Pharmaceutical companies are increasingly investing in R&D activities aimed at developing novel therapeutics for treating cardiovascular disorders .This is
Scope Of The Report
Report Attributes
Report Details
Report Title
Atenolol API Market Research Report
By Type
Purity ≥ 98 %, Purity ≥ 99 %
By Application
Tablets, Injection, Others
By Companies
Tapi-Teva API, Ipca Laboratories, Vani Pharma Labs, Triveni Interchem, Reine Lifescience, Kopran Limited, Sai Supreme Chemicals, Tapi-Teva API
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Atenolol API Market Report Segments:
The global Atenolol API market is segmented on the basis of:
Types
Purity ≥ 98 %, Purity ≥ 99 %
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Tablets, Injection, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Tapi-Teva API
- Ipca Laboratories
- Vani Pharma Labs
- Triveni Interchem
- Reine Lifescience
- Kopran Limited
- Sai Supreme Chemicals
- Tapi-Teva API
Highlights of The Atenolol API Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Purity ≥ 98 %
- Purity ≥ 99 %
- By Application:
- Tablets
- Injection
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Atenolol API Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Atenolol API is a generic name for the active pharmaceutical ingredient (API) of atenolol.
Some of the key players operating in the atenolol api market are Tapi-Teva API, Ipca Laboratories, Vani Pharma Labs, Triveni Interchem, Reine Lifescience, Kopran Limited, Sai Supreme Chemicals, Tapi-Teva API.
The atenolol api market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Atenolol API Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Atenolol API Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Atenolol API Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Atenolol API Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Atenolol API Market Size & Forecast, 2018-2028
4.5.1 Atenolol API Market Size and Y-o-Y Growth
4.5.2 Atenolol API Market Absolute $ Opportunity
Chapter 5 Global Atenolol API Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Atenolol API Market Size Forecast by Type
5.2.1 Purity ≥ 98 %
5.2.2 Purity ≥ 99 %
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Atenolol API Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Atenolol API Market Size Forecast by Applications
6.2.1 Tablets
6.2.2 Injection
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Atenolol API Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Atenolol API Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Atenolol API Analysis and Forecast
9.1 Introduction
9.2 North America Atenolol API Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Atenolol API Market Size Forecast by Type
9.6.1 Purity ≥ 98 %
9.6.2 Purity ≥ 99 %
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Atenolol API Market Size Forecast by Applications
9.10.1 Tablets
9.10.2 Injection
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Atenolol API Analysis and Forecast
10.1 Introduction
10.2 Europe Atenolol API Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Atenolol API Market Size Forecast by Type
10.6.1 Purity ≥ 98 %
10.6.2 Purity ≥ 99 %
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Atenolol API Market Size Forecast by Applications
10.10.1 Tablets
10.10.2 Injection
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Atenolol API Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Atenolol API Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Atenolol API Market Size Forecast by Type
11.6.1 Purity ≥ 98 %
11.6.2 Purity ≥ 99 %
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Atenolol API Market Size Forecast by Applications
11.10.1 Tablets
11.10.2 Injection
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Atenolol API Analysis and Forecast
12.1 Introduction
12.2 Latin America Atenolol API Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Atenolol API Market Size Forecast by Type
12.6.1 Purity ≥ 98 %
12.6.2 Purity ≥ 99 %
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Atenolol API Market Size Forecast by Applications
12.10.1 Tablets
12.10.2 Injection
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Atenolol API Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Atenolol API Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Atenolol API Market Size Forecast by Type
13.6.1 Purity ≥ 98 %
13.6.2 Purity ≥ 99 %
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Atenolol API Market Size Forecast by Applications
13.10.1 Tablets
13.10.2 Injection
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Atenolol API Market: Competitive Dashboard
14.2 Global Atenolol API Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Tapi-Teva API
14.3.2 Ipca Laboratories
14.3.3 Vani Pharma Labs
14.3.4 Triveni Interchem
14.3.5 Reine Lifescience
14.3.6 Kopran Limited
14.3.7 Sai Supreme Chemicals
14.3.8 Tapi-Teva API
